Latest news
25 items- PRIDEAYA Biosciences Appoints Douglas B. Snyder as Senior Vice President, General CounselOver 25 years of legal experience with leading healthcare organizations, including GW Pharmaceuticals, Actelion Pharmaceuticals, Eisai, GSK, and the U.S. FDASOUTH SAN FRANCISCO, Calif., Sept. 18, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that Douglas B. Snyder, joined the company as its Senior Vice President, General Counsel on September 18, 2024. "Doug brings a broad legal background in the healthcare field spanning biotechnology, pharm
- NEWSJazz Pharmaceuticals Files Patent Infringement Against Generic Drugmakers In New Jersey's District CourtJazz Pharmaceuticals (NASDAQ:JAZZ), a drug company behind the CBD-based medication Epidiolex, recently filed a lawsuit against Teva Pharmaceutical Industries Ltd (NYSE:TEVA), Apotex, Alkem and several other generic drugmakers alleging patent infringement on the cannabis-derived therapy. Epidiolex, which won its U.S. Food and Drug Administration (FDA) approval in 2018 and 2020 as the first therapy comprised of an active ingredient derived from cannabis, treats seizures from Lennox-Gastaut Syndrome (“LGS”), Dravet Syndrome (“DS”), and Tuberous Sclerosis Complex (“TSC”), all of which are rare diseases characterized by severe early-onset epilepsy. What Happened According to the lawsuit, filed
- NEWSStudy Suggests Whole-Plant Medicinal Cannabis Could Be More Effective Than CBD In Epilepsy TreatmentEpileptic seizure frequency fell by an average of 86% among ten children treated with whole-plant medicinal cannabis, reveals a case series published in the open-access journal BMJ Paediatrics Open. None of the children had responded to other treatments, including the only cannabidiol (CBD) product licensed for their condition, reported medicalexpress.com Prompted by parents whose children had responded well to whole plant medicinal cannabis extracts, but not to conventional antiepileptic drugs or purified cannabidiol (CBD oil), medicinal (whole plant) cannabis was designated a prescription medicine for the treatment of severe childhood epilepsy in 2018. Whole plant cannabis includes THC,
- SECSEC Form 15-12B filed by GW Pharmaceuticals Plc15-12B - GW PHARMACEUTICALS PLC (0001351288) (Filer)
- INSIDERSEC Form 4: Tovey Christopher J. returned 2,496 units of Ordinary Shares to the company, decreasing direct ownership by 100% to 0 units4 - GW PHARMACEUTICALS PLC (0001351288) (Issuer)
- INSIDERSEC Form 4: Cline Darren S returned 5,556 units of Ordinary Shares to the company, decreasing direct ownership by 100% to 0 units4 - GW PHARMACEUTICALS PLC (0001351288) (Issuer)
- INSIDERSEC Form 4 filed by GRYSKA DAVID W4 - GW PHARMACEUTICALS PLC (0001351288) (Issuer)
- INSIDERSEC Form 4: Giacobello Scott M. returned 165,108 units of Ordinary Shares to the company, decreasing direct ownership by 100% to 0 units4 - GW PHARMACEUTICALS PLC (0001351288) (Issuer)
- INSIDERSEC Form 4: Secor Alicia returned 10,584 units of Ordinary Shares to the company, decreasing direct ownership by 100% to 0 units4 - GW PHARMACEUTICALS PLC (0001351288) (Issuer)
- INSIDERSEC Form 4: Knappertz Volker returned 92,412 units of Ordinary Shares to the company, decreasing direct ownership by 100% to 0 units4 - GW PHARMACEUTICALS PLC (0001351288) (Issuer)
- INSIDERSEC Form 4: MACKEY CATHERINE J returned 10,536 units of Ordinary Shares to the company, decreasing direct ownership by 100% to 0 units4 - GW PHARMACEUTICALS PLC (0001351288) (Issuer)
- INSIDERSEC Form 4: Noble James returned 27,492 units of Ordinary Shares to the company, decreasing direct ownership by 100% to 0 units4 - GW PHARMACEUTICALS PLC (0001351288) (Issuer)
- INSIDERSEC Form 4: Gover Justin D. returned 2,546,129 units of Ordinary Shares to the company, decreasing direct ownership by 100% to 0 units4 - GW PHARMACEUTICALS PLC (0001351288) (Issuer)
- INSIDERSEC Form 4: Snyder Douglas B. returned 61,848 units of Ordinary Shares to the company, decreasing direct ownership by 100% to 0 units4 - GW PHARMACEUTICALS PLC (0001351288) (Issuer)
- INSIDERSEC Form 4: Brown Cabot returned 7,200 units of Ordinary Shares to the company, decreasing direct ownership by 100% to 0 units4 - GW PHARMACEUTICALS PLC (0001351288) (Issuer)
- INSIDERSEC Form 4: GUY GEOFFREY W DR returned 4,910,446 units of Ordinary Shares to the company, decreasing direct ownership by 100% to 0 units4 - GW PHARMACEUTICALS PLC (0001351288) (Issuer)
- INSIDERSEC Form 4 filed by Waldegrave William A.4 - GW PHARMACEUTICALS PLC (0001351288) (Issuer)
- SECSEC Form S-8 POS filed by GW Pharmaceuticals PlcS-8 POS - GW PHARMACEUTICALS PLC (0001351288) (Filer)
- SECSEC Form S-8 POS filed by GW Pharmaceuticals PlcS-8 POS - GW PHARMACEUTICALS PLC (0001351288) (Filer)
- SECSEC Form S-8 POS filed by GW Pharmaceuticals PlcS-8 POS - GW PHARMACEUTICALS PLC (0001351288) (Filer)
- SECSEC Form POSASR filed by GW Pharmaceuticals PlcPOSASR - GW PHARMACEUTICALS PLC (0001351288) (Filer)
- SECGW Pharmaceuticals Plc filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Other Events, Financial Statements and Exhibits8-K - GW PHARMACEUTICALS PLC (0001351288) (Filer)
- PRJazz Pharmaceuticals Completes Acquisition of GW Pharmaceuticals plcDUBLIN, May 5, 2021 /PRNewswire/ -- Jazz Pharmaceuticals (NASDAQ:JAZZ) today announced the completion of its acquisition of GW Pharmaceuticals plc (NASDAQ:GWPH) ("GW"), a leader in the science, development and commercialization of cannabinoid-based prescription medicines. "We are excited to welcome our GW colleagues to Jazz as we mark a transformative milestone in creating an innovative, high-growth, global biopharma leader in neuroscience with a worldwide commercial and operational footprint," said Bruce Cozadd, chairman and chief executive officer of Jazz Pharmaceuticals. "The addition of GW further diversifies our commerical portfolio and innovative pipeline with therapies that are compl
- SECSEC Form 25-NSE filed by GW Pharmaceuticals Plc25-NSE - GW PHARMACEUTICALS PLC (0001351288) (Subject)
- SECSEC Form 10-K/A filed by GW Pharmaceuticals Plc (Amendment)10-K/A - GW PHARMACEUTICALS PLC (0001351288) (Filer)
GWPH FAQ
5 questionsWhere does GWPH stock trade?
GW Pharmaceuticals Plc (GWPH) is listed on NASDAQ.What sector and industry is GWPH in?
GW Pharmaceuticals Plc operates in the Health Care sector, Major Pharmaceuticals industry.When did GW Pharmaceuticals Plc go public?
GW Pharmaceuticals Plc (GWPH) completed its IPO in 2013.What companies are similar to GWPH?
Notable peers in the same industry include DRNA (Dicerna Pharmaceuticals, Inc.), TRIL (Trillium Therapeutics Inc.), KDMN (Kadmon Holdings, Inc.), FLXN (Flexion Therapeutics, Inc.), ARPO (Aerpio Pharmaceuticals, Inc.). Compare GWPH side-by-side with any of them on Quantisnow.How can I track GWPH on Quantisnow?
Quantisnow aggregates GW Pharmaceuticals Plc's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow GWPH to receive live email and push alerts on every new disclosure.